These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31647967)

  • 21. Increased Production of LIGHT by T Cells in Eosinophilic Esophagitis Promotes Differentiation of Esophageal Fibroblasts Toward an Inflammatory Phenotype.
    Manresa MC; Chiang AWT; Kurten RC; Dohil R; Brickner H; Dohil L; Herro R; Akuthota P; Lewis NE; Croft M; Aceves SS
    Gastroenterology; 2020 Nov; 159(5):1778-1792.e13. PubMed ID: 32712105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen Activator Inhibitor-1 as a Marker of Esophageal Functional Changes in Pediatric Eosinophilic Esophagitis.
    Williamson P; Proudfoot J; Gharibans A; Dohil L; Newbury R; Barsamian J; Hassan M; Rawson R; Katzka D; Kurten R; Dohil R; Mousa H; Aceves S
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):57-64.e3. PubMed ID: 33007513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of the Eosinophilic Esophagitis Histologic Scoring System in Distinguishing Active Eosinophilic Esophagitis From Remission and Gastroesophageal Reflux Disease.
    Lin B; Rabinowitz S; Haseeb MA; Gupta R
    Gastroenterology Res; 2021 Aug; 14(4):220-226. PubMed ID: 34527091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of para-esophageal lymph nodes in food or aeroallergen-induced iNKT cell-mediated experimental eosinophilic esophagitis.
    Rajavelu P; Rayapudi M; Moffitt M; Mishra A; Mishra A
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(7):G645-54. PubMed ID: 22207581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical differentiation of eosinophilic esophageal myositis from eosinophilic esophagitis.
    Sato H; Nakajima N; Hasegawa G; Kawata Y; Sato Y; Suzuki K; Honma T; Terai S
    J Gastroenterol Hepatol; 2017 Jan; 32(1):106-113. PubMed ID: 27262491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRC31 is induced by IL-13 and regulates kallikrein expression and barrier function in the esophageal epithelium.
    D'Mello RJ; Caldwell JM; Azouz NP; Wen T; Sherrill JD; Hogan SP; Rothenberg ME
    Mucosal Immunol; 2016 May; 9(3):744-56. PubMed ID: 26462420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGF-β1 alters esophageal epithelial barrier function by attenuation of claudin-7 in eosinophilic esophagitis.
    Nguyen N; Fernando SD; Biette KA; Hammer JA; Capocelli KE; Kitzenberg DA; Glover LE; Colgan SP; Furuta GT; Masterson JC
    Mucosal Immunol; 2018 Mar; 11(2):415-426. PubMed ID: 28832026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD73
    Hara T; Kasagi Y; Wang J; Sasaki M; Aaron B; Karami A; Shimonosono M; Shimonosono R; Maekawa H; Dolinsky L; Wilkins B; Klein J; Wei J; Nunes K; Lynch K; Spergel JM; Hamilton KE; Ruffner MA; Karakasheva TA; Whelan KA; Nakagawa H; Muir AB
    Cell Mol Gastroenterol Hepatol; 2022; 13(5):1449-1467. PubMed ID: 35108658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis.
    Avlas S; Shani G; Rhone N; Itan M; Dolitzky A; Hazut I; Grisaru-Tal S; Gordon Y; Shoda T; Ballaban A; Ben-Baruch NM; Rochman M; Diesendruck Y; Nahary L; Bitton A; Halpern Z; Benhar I; Varol C; Rothenberg ME; Munitz A
    Allergy; 2023 Feb; 78(2):464-476. PubMed ID: 36070083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, and remodeling in experimental eosinophilic esophagitis.
    Collison AM; Sokulsky LA; Sherrill JD; Nightingale S; Hatchwell L; Talley NJ; Walker MM; Rothenberg ME; Mattes J
    J Allergy Clin Immunol; 2015 Oct; 136(4):971-82. PubMed ID: 25981737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profound loss of esophageal tissue differentiation in patients with eosinophilic esophagitis.
    Rochman M; Travers J; Miracle CE; Bedard MC; Wen T; Azouz NP; Caldwell JM; Kc K; Sherrill JD; Davis BP; Rymer JK; Kaufman KM; Aronow BJ; Rothenberg ME
    J Allergy Clin Immunol; 2017 Sep; 140(3):738-749.e3. PubMed ID: 28104354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proposed criteria to differentiate heterogeneous eosinophilic gastrointestinal disorders of the esophagus, including eosinophilic esophageal myositis.
    Sato H; Nakajima N; Takahashi K; Hasegawa G; Mizuno KI; Hashimoto S; Ikarashi S; Hayashi K; Honda Y; Yokoyama J; Sato Y; Terai S
    World J Gastroenterol; 2017 Apr; 23(13):2414-2423. PubMed ID: 28428721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis.
    Rieder F; Nonevski I; Ma J; Ouyang Z; West G; Protheroe C; DePetris G; Schirbel A; Lapinski J; Goldblum J; Bonfield T; Lopez R; Harnett K; Lee J; Hirano I; Falk G; Biancani P; Fiocchi C
    Gastroenterology; 2014 May; 146(5):1266-77.e1-9. PubMed ID: 24486052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.
    Nhu QM; Hsieh L; Dohil L; Dohil R; Newbury RO; Kurten R; Moawad FJ; Aceves SS
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00164. PubMed ID: 32352681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered esophageal histamine receptor expression in Eosinophilic Esophagitis (EoE): implications on disease pathogenesis.
    Merves J; Chandramouleeswaran PM; Benitez AJ; Muir AB; Lee AJ; Lim DM; Dods K; Mehta I; Ruchelli ED; Nakagawa H; Spergel JM; Wang ML
    PLoS One; 2015; 10(2):e0114831. PubMed ID: 25723478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis.
    Rubinstein E; Cho JY; Rosenthal P; Chao J; Miller M; Pham A; Aceves SS; Varki A; Broide DH
    J Pediatr Gastroenterol Nutr; 2011 Oct; 53(4):409-16. PubMed ID: 21970996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis.
    Simon D; Page B; Vogel M; Bussmann C; Blanchard C; Straumann A; Simon HU
    Allergy; 2018 Jan; 73(1):239-247. PubMed ID: 28712126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation.
    Simon D; Radonjic-Hösli S; Straumann A; Yousefi S; Simon HU
    Allergy; 2015 Apr; 70(4):443-52. PubMed ID: 25620273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smad3-deficient mice have reduced esophageal fibrosis and angiogenesis in a model of egg-induced eosinophilic esophagitis.
    Cho JY; Doshi A; Rosenthal P; Beppu A; Miller M; Aceves S; Broide D
    J Pediatr Gastroenterol Nutr; 2014 Jul; 59(1):10-6. PubMed ID: 24590208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Expression of ICAM-1 in Blood Eosinophils in Patients With Active Eosinophilic Esophagitis.
    Perez-Lucendo I; Gomez Torrijos E; Donado P; Melero R; Feo-Brito F; Urra JM
    J Investig Allergol Clin Immunol; 2021 Jul; 31(4):316-321. PubMed ID: 31983676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.